Last reviewed · How we verify
LY450139
LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.
LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein. Used for Alzheimer's disease (mild cognitive impairment and mild dementia stages).
At a glance
| Generic name | LY450139 |
|---|---|
| Also known as | semagacestat, Semagacestat |
| Sponsor | Eli Lilly and Company |
| Drug class | Gamma-secretase inhibitor |
| Target | Gamma-secretase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Gamma-secretase is an intramembrane protease complex responsible for the final cleavage step in amyloid-beta generation. By inhibiting this enzyme, LY450139 decreases amyloid-beta production in the brain, which is hypothesized to slow cognitive decline in Alzheimer's disease. This approach targets the amyloid hypothesis of neurodegeneration.
Approved indications
- Alzheimer's disease (mild cognitive impairment and mild dementia stages)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Skin rash
- Cognitive/neurological effects
Key clinical trials
- Effect of LY450139 on the Long Term Progression of Alzheimer's Disease (PHASE3)
- Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (PHASE3)
- A Study of Semagacestat for Alzheimer's Patients (PHASE3)
- A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response. (PHASE1)
- Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY450139 CI brief — competitive landscape report
- LY450139 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI